rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    VNRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Earnings call transcript: VolitionRx tops Q3 2026 estimates as revenue jumps 157%
      Nov 13Investing.comVNRX
      VolitionRx Limited Q3 2026 Earnings Call Summary
      Nov 13Yahoo FinanceVNRX
      Volitionrx Ltd earnings beat by $0.18, revenue topped estimates
      Nov 13Investing.comVNRX
      VolitionRX: Q3 Earnings Snapshot
      Nov 12Yahoo FinanceVNRX
      VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update

      VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the third quarter of 2026. Volition management will host a conference call tomorrow, November 13 at 8:30 a.m. U.S. Eastern Time/2:30 p.m. Central European Time to discuss these results. Conference call details can be found below.

      Nov 12Yahoo FinanceVNRX
      Earnings To Watch: VolitionRX Ltd (VNRX) Q3 2026 -- GF Value Sees 10730.00% Upside
      Nov 12Yahoo FinanceVNRX
      Earnings to Watch: VolitionRX Ltd (VNRX) Q3 2026 -- GF Value Sees 11857.70% Upside
      Nov 11Yahoo FinanceVNRX
      VolitionRx Limited Schedules Third Quarter 2026 Earnings Conference Call and Business Update
      Nov 9Yahoo FinanceVNRX
      VolitionRx signs letter of intent with Missionpharma
      Oct 27Investing.comVNRX
      VolitionRx prepays $500,000 on convertible note to Lind
      Oct 27Investing.comVNRX
      VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide
      Oct 27Yahoo FinanceVNRX
      VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash
      Oct 27Yahoo FinanceVNRX
      VolitionRx Uses Private Equity Issuance to Reduce Debt

      Detailed price information for Volitionrx Ltd (VNRX-A) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailVNRX
      VolitionRx joins France sepsis detection consortium
      Sep 17Investing.comVNRX
      VolitionRx Participates in Launch of DETECSEPS Program in France
      Sep 17Yahoo FinanceVNRX
      VolitionRx Participates in Launch of DETECSEPS Program in France – Company Announcement
      Sep 17Financial TimesVNRX
      VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
      Sep 17Yahoo FinanceVNRX
      VolitionRx issues shares for note conversions, updates outstanding share count
      Sep 16Investing.comVNRX
      VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

      By Steven Ralston, CFA NYSE: VNRX READ THE FULL VNRX RESEARCH REPORT EXECUTIVE OVERVIEW VolitionRx Limited (NYSE: VNRX) continues to advance its multi-pillar epigenetics platform through mid-2026, generating a continued stream of clinical validation across Nu.Q NETs, Nu.Q Cancer, and Capture-Seq. Management has simultaneously decreased operating expenses, which were reduced in the most recent

      Sep 14Yahoo FinanceVNRX
      VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

      VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the full pre-payment in cash of the outstanding balance on its senior secured convertible promissory note, dated May 20, 2025, in the original principal amount of $7,500,000 (the "Note"), issued to Lind Global Asset Management XII LLC ("Lind"). Following the pre-payment, all obligations under the Note have been satisfied. The senior secured convertible promissory note, dated January 7, 20

      Sep 14Yahoo FinanceVNRX
      VolitionRx Files for Secondary Offering of Common Shares

      VolitionRx (VNRX) filed a registration statement late Friday for the sale of over 10 million common

      Aug 28Yahoo FinanceVNRX
      12 Health Care Stocks Moving In Thursday's Pre-Market Session
      Aug 27BenzingaVNRX
      Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations

      VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations. The multi-national epigenetics firm demonstrated strong momentum across its core diagnostic verticals, including sepsis monitoring, human oncology detection, and companion animal health, positioning the company to address total market opportunities exceeding $2

      Aug 27Yahoo FinanceVNRX
      VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

      VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.

      Aug 26Yahoo FinanceVNRX

      This is the newest page. Registered accounts read further back.